Cargando…
A comprehensive review and characterization of nasopharyngeal carcinoma clinical trials
OBJECTIVE: Although standard of care for primary nasopharyngeal carcinoma (NPC) is chemoradiotherapy, there remains no consensus on management of recurrent or metastatic disease. We characterized recent clinical trials on NPC to assess trends in NPC treatment and establish promising areas for future...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296046/ https://www.ncbi.nlm.nih.gov/pubmed/37383331 http://dx.doi.org/10.1002/wjo2.80 |
_version_ | 1785063565199147008 |
---|---|
author | Xu, Katherine De Ravin, Emma Suresh, Neeraj Brody, Robert M. Rajasekaran, Karthik |
author_facet | Xu, Katherine De Ravin, Emma Suresh, Neeraj Brody, Robert M. Rajasekaran, Karthik |
author_sort | Xu, Katherine |
collection | PubMed |
description | OBJECTIVE: Although standard of care for primary nasopharyngeal carcinoma (NPC) is chemoradiotherapy, there remains no consensus on management of recurrent or metastatic disease. We characterized recent clinical trials on NPC to assess trends in NPC treatment and establish promising areas for future research. STUDY DESIGN: Retrospective database study. SETTING: ClinicalTrials.gov database. METHODS: Retrospective review of all NPC trials from November 1999 to June 2021. For each study, the following variables were extracted: study characteristics, intervention, outcome measures, and inclusion criteria. Secondary searches via PubMed and Google scholar determined trial publication status. RESULTS: A total of 448 clinical trials were identified: 72 (16%) observational and 376 (84%) interventional, of which there were 30 (8%) Phase I, 183 (49%) Phase II, 86 Phase III (23%), and 5 (1%) Phase IV trials. Fifty‐four percent of trials included only primary NPC while 111 (25%) exclusively studied recurrent cancers. The most common interventions were cisplatin (n = 64) and intensity modulated radiation therapy (n = 54); there were 38 trials involving PD‐1 monoclonal antibodies. Thirty‐four studies examined quality of life measures, including xerostomia and mucositis. Of the completed studies, 53.2% have published manuscripts. Poor patient accrual was the most common reason for premature study termination. CONCLUSIONS: Novel immunotherapies have been increasingly incorporated into NPC studies in recent years, however, chemotherapy and radiation, despite their numerous side effects, are still widely used due to their clinical effectiveness. Future trials are warranted to determine the optimal therapeutic regimens to decrease relapse rates and side effects. |
format | Online Article Text |
id | pubmed-10296046 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102960462023-06-28 A comprehensive review and characterization of nasopharyngeal carcinoma clinical trials Xu, Katherine De Ravin, Emma Suresh, Neeraj Brody, Robert M. Rajasekaran, Karthik World J Otorhinolaryngol Head Neck Surg Research Papers OBJECTIVE: Although standard of care for primary nasopharyngeal carcinoma (NPC) is chemoradiotherapy, there remains no consensus on management of recurrent or metastatic disease. We characterized recent clinical trials on NPC to assess trends in NPC treatment and establish promising areas for future research. STUDY DESIGN: Retrospective database study. SETTING: ClinicalTrials.gov database. METHODS: Retrospective review of all NPC trials from November 1999 to June 2021. For each study, the following variables were extracted: study characteristics, intervention, outcome measures, and inclusion criteria. Secondary searches via PubMed and Google scholar determined trial publication status. RESULTS: A total of 448 clinical trials were identified: 72 (16%) observational and 376 (84%) interventional, of which there were 30 (8%) Phase I, 183 (49%) Phase II, 86 Phase III (23%), and 5 (1%) Phase IV trials. Fifty‐four percent of trials included only primary NPC while 111 (25%) exclusively studied recurrent cancers. The most common interventions were cisplatin (n = 64) and intensity modulated radiation therapy (n = 54); there were 38 trials involving PD‐1 monoclonal antibodies. Thirty‐four studies examined quality of life measures, including xerostomia and mucositis. Of the completed studies, 53.2% have published manuscripts. Poor patient accrual was the most common reason for premature study termination. CONCLUSIONS: Novel immunotherapies have been increasingly incorporated into NPC studies in recent years, however, chemotherapy and radiation, despite their numerous side effects, are still widely used due to their clinical effectiveness. Future trials are warranted to determine the optimal therapeutic regimens to decrease relapse rates and side effects. John Wiley and Sons Inc. 2022-09-30 /pmc/articles/PMC10296046/ /pubmed/37383331 http://dx.doi.org/10.1002/wjo2.80 Text en © 2022 The Authors. World Journal of Otorhinolaryngology ‐ Head and Neck Surgery published by John Wiley & Sons Ltd on behalf of Chinese Medical Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Papers Xu, Katherine De Ravin, Emma Suresh, Neeraj Brody, Robert M. Rajasekaran, Karthik A comprehensive review and characterization of nasopharyngeal carcinoma clinical trials |
title | A comprehensive review and characterization of nasopharyngeal carcinoma clinical trials |
title_full | A comprehensive review and characterization of nasopharyngeal carcinoma clinical trials |
title_fullStr | A comprehensive review and characterization of nasopharyngeal carcinoma clinical trials |
title_full_unstemmed | A comprehensive review and characterization of nasopharyngeal carcinoma clinical trials |
title_short | A comprehensive review and characterization of nasopharyngeal carcinoma clinical trials |
title_sort | comprehensive review and characterization of nasopharyngeal carcinoma clinical trials |
topic | Research Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296046/ https://www.ncbi.nlm.nih.gov/pubmed/37383331 http://dx.doi.org/10.1002/wjo2.80 |
work_keys_str_mv | AT xukatherine acomprehensivereviewandcharacterizationofnasopharyngealcarcinomaclinicaltrials AT deravinemma acomprehensivereviewandcharacterizationofnasopharyngealcarcinomaclinicaltrials AT sureshneeraj acomprehensivereviewandcharacterizationofnasopharyngealcarcinomaclinicaltrials AT brodyrobertm acomprehensivereviewandcharacterizationofnasopharyngealcarcinomaclinicaltrials AT rajasekarankarthik acomprehensivereviewandcharacterizationofnasopharyngealcarcinomaclinicaltrials AT xukatherine comprehensivereviewandcharacterizationofnasopharyngealcarcinomaclinicaltrials AT deravinemma comprehensivereviewandcharacterizationofnasopharyngealcarcinomaclinicaltrials AT sureshneeraj comprehensivereviewandcharacterizationofnasopharyngealcarcinomaclinicaltrials AT brodyrobertm comprehensivereviewandcharacterizationofnasopharyngealcarcinomaclinicaltrials AT rajasekarankarthik comprehensivereviewandcharacterizationofnasopharyngealcarcinomaclinicaltrials |